Financials data is unavailable for this security.
View more
Year on year Percheron Therapeutics Ltd had net income fall 4.74% from a loss of 11.38m to a larger loss of 11.92m despite a 59.90% increase in revenues from 384.92k to 615.48k.
| Gross margin | -- |
|---|---|
| Net profit margin | -1,936.57% |
| Operating margin | -2,317.53% |
| Return on assets | -87.09% |
|---|---|
| Return on equity | -123.27% |
| Return on investment | -122.82% |
More ▼
Cash flow in AUDView more
In 2024, Percheron Therapeutics Ltd increased its cash reserves by 8.20%, or 899.40k. Cash Flow from Financing totalled 11.02m or 1,790.29% of revenues. In addition the company used 10.12m for operations while cash used for investing totalled 3.61k.
| Cash flow per share | -0.0134 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0104 |
|---|---|
| Tangible book value per share | 0.0104 |
More ▼
Balance sheet in AUDView more
| Current ratio | 2.81 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0043 |
|---|---|
| Total debt/total capital | 0.0042 |
More ▼
